Grail (NASDAQ:GRAL) Coverage Initiated at Wolfe Research

Wolfe Research started coverage on shares of Grail (NASDAQ:GRAL) in a research report sent to investors on Friday, MarketBeat reports. The firm issued a peer perform rating on the stock.

Separately, Guggenheim started coverage on Grail in a research report on Thursday, October 17th. They set a “neutral” rating for the company.

Grail Price Performance

Shares of Grail stock traded down $1.01 during trading on Friday, hitting $14.80. 832,534 shares of the company were exchanged, compared to its average volume of 1,094,071. Grail has a fifty-two week low of $12.33 and a fifty-two week high of $23.36. The stock has a 50 day moving average of $13.82.

Grail (NASDAQ:GRAL) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($5.30) earnings per share for the quarter. The business had revenue of $31.97 million during the quarter.

Insiders Place Their Bets

In other news, CEO Robert P. Ragusa sold 123,454 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the completion of the transaction, the chief executive officer now owns 612,661 shares of the company’s stock, valued at $8,589,507.22. This represents a 16.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Chun R. Ding bought 35,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 3rd. The stock was bought at an average cost of $12.71 per share, for a total transaction of $444,850.00. Following the completion of the transaction, the insider now directly owns 3,558,655 shares of the company’s stock, valued at approximately $45,230,505.05. The trade was a 0.99 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders bought 58,829 shares of company stock valued at $757,298.

About Grail

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.